TELESTA THERAPEUTICS INC T.TST

How soon Investwerp forgets

[somweyungguy]

image: https://www.stockhouse.com/CMSModules/Avatars/CMSPages/GetAvatar.aspx?maxsidesize=38&avatarguid=42f9d97e-b0c8-43a2-8a35-62dfec5ae64a

investderp

image: https://www.stockhouse.com/Stockhouse/images/stars-mask.png

May 25, 2011 - 08:22 PM 236 Reads
Post# 18625778

Rate this post

image: https://www.stockhouse.com/Stockhouse/images/stars-mask.png

RE: RE: RE: RE: RE: More media exposure...print ve

bailmeout, the first PhaseIII trial for which data was presented on, was "Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer"

The second and currently recruiting trial is "Efficacy and Safety Evaluation of EN3348(Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin Cin the Intravesical Treatment of Subjects With BCG Recurrent/RefractoryNon-muscle Invasive Bladder Cancer (EMBARC-RF)". Both mention BCG refractory, however the second one also includes patients who aren't disease free where a recurrence occurs.

Read more at https://www.stockhouse.com/companies/bullboard/bullboard/t.tst/telesta-therapeutics-inc#pqEDp1e0b2d0iQcK.99

[investderp]

How soon you forget... Population Description Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. Too few events reported so the event-free survival rate cannot be calculated.

[somweyungguy]

As previously mentioned.."we won't allow a double dip of negativity on the ENDO experience" ( PS - Seeking Alpha, they already own a piece of us ) SAFETY is job #1 at the FDA..the safety profile of each and every one of the 100 or so patients enrolled would have been closely watched and detialed by the FDA. Add the 25% to 32% effcacy and you have a positive ADCOM and the answer to